Deletion of the MAP3K7 gene occurs in 30–40% of prostate tumours, and is associated with a poor clinical prognosis (Goodall et al., 2016; Kluth et al., 2013; Liu et al., 2007; Wu et al., 2012). Here, MAP3K7 is linked to prostate neoplasm.